gutsandgrowth

Home | About Jay Hochman -Pediatric Gastroenterology Blog | Archives

Treating Pediatric Hepatitis C Infections is Cost-Effective. Plus COVID-19 mRNA Vaccine Study

December 13, 2020 9:00 am

E Greenaway et al. J Pediatr 2020; DOI:https://doi.org/10.1016/j.jpeds.2020.08.088. Free full text: Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood

Methods: A state-transition model of chronic HCV was developed to conduct a cost-effectiveness analysis comparing treatment at age 6 years vs delaying treatment until age 18 years

Key findings:

• After 20 years, treating 10 000 children early would prevent 330 cases of cirrhosis, 18 cases of hepatocellular carcinoma, and 48 liver-related deaths
• The incremental cost-effectiveness ratio of early treatment compared to delayed treatment was approximately $12 690/quality-adjusted life-years gained and considered cost-effective

My take (=conclusion from authors): Delaying treatment until age 18 years results in an increased lifetime risk of late-stage liver complications. Early treatment in children is cost effective. Our work supports clinical and health policies that broaden HCV treatment access to young children.

Related blog posts:

• Hepatitis C in 2020: NASPGHAN Position Paper -includes the following: “We recommend treatment be considered and offered to all children with chronic HCV as early as 3 years of age with currently approved and anticipated DAA combination therapies”
• Online Aspen Webinar (Part 4 -Hepatitis C 2020)
• Medical Progress: Toward Hepatitis C Elimination (2020 Pediatric Treatment Algorithms)
• ‘Crushing it:” Practice Guidance for Hepatitis C
• Resolution: Eradication of Hepatitis C
• Pediatric HCV Guidelines
• “Crushing it:” Two More Pediatric Hepatitis C Trials
• Hepatitis C Infections Increasing -Tied to Opioid Crisis
• Hepatitis C Cure: Too Late for Many | gutsandgrowth

FP Polack et al. NEJM Full text link: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Posted by gutsandgrowth

Categories: hepatitis C, Pediatric Gastroenterology Liver Disease

Tags: COVID-19, Hepatiits C, vaccine

« Older Newer »

Mobile Site | Full Site

Get a free blog at WordPress.com Theme: WordPress Mobile Edition by Alex King.